MaxCyte's Upcoming Investor Engagements
MaxCyte, Inc. (NASDAQ: MXCT), a pioneer in cell engineering technologies, is gearing up to take part in two notable investor conferences. These events provide an excellent platform for the company to showcase its innovative advancements in cell-based therapeutics and engage directly with investors seeking insights into the future of the biopharmaceutical landscape.
Stifel 2024 Healthcare Conference
One of the key events on the horizon is the Stifel 2024 Healthcare Conference. MaxCyte's management team will host a Fireside Chat on Monday, November 18, where they will articulate the company's vision and discuss the growth opportunities within the sector. This session will start at 10:55 AM ET. It's a moment to highlight how their technologies integrate into the rapidly evolving field of cell therapy.
Stephens Annual Investment Conference
Following the Stifel event, MaxCyte will also participate in the Stephens Annual Investment Conference on Tuesday, November 19. The discussion is set to take place during a Fireside Chat at 3:00 PM CT. This conference will allow the executives of MaxCyte to connect with both current and potential investors in a more personal setting, sharing their insights on driving innovation and how they are addressing market needs through their advanced technologies.
Access to Event Recordings
For those unable to attend, MaxCyte will provide a live and archived webcast of both events through their investor relations website. This enables a broader audience to gain knowledge on how MaxCyte is shaping the future of cell-based therapies. These webcasts are not just informative, but they also encapsulate the passion and dedication of the team behind MaxCyte as they journey towards transforming human health.
About MaxCyte
MaxCyte is firmly committed to pushing the boundaries of cell engineering to enhance the effectiveness of cell-based therapies. Over the last 20 years, the company has developed an expertise that stands tall in the biotechnology sector. Their ExPERT™ platform is a testament to this legacy, providing a cutting-edge solution that equips researchers and developers with the tools necessary for efficient transfection processes.
The ExPERT family boasts several innovative instruments like the ATx™, STx™, GTx™, and VLx™, which are designed to support the entire lifecycle of cell therapy products, from discovery through to commercialization. Coupled with a rich portfolio of intellectual property and comprehensive support, MaxCyte thrives on empowering its partners to realize breakthroughs that enhance patient lives.
Connecting with MaxCyte
MaxCyte encourages collaboration and communication within the scientific community. Interested parties can learn more about their technologies and explore potential partnerships by visiting the official website. They are also active on various social media platforms to keep stakeholders engaged and informed about their latest developments and innovations.
Frequently Asked Questions
What is MaxCyte, Inc. known for?
MaxCyte is a leader in cell engineering technologies, focusing on enabling cell-based therapeutics to improve patient outcomes.
When will MaxCyte participate in the Stifel Healthcare Conference?
MaxCyte's management will host a Fireside Chat at the Stifel Healthcare Conference on November 18 at 10:55 AM ET.
How can investors access the conference webcasts?
Investors can access live and archived webcasts on MaxCyte's investor relations website for both conferences.
What technologies does MaxCyte offer?
MaxCyte offers the ExPERT™ platform, along with various instruments and proprietary processing assemblies designed to support cell therapy.
How can I get in touch with MaxCyte's Investor Relations?
For inquiries, you can reach MaxCyte's Investor Relations through their official website or by contacting their dedicated IR team directly.